We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+3.21%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$31.1B
AUM Growth
Cap. Flow
+$31.1B
Cap. Flow %
99.86%
Top 10 Hldgs %
15.32%
Holding
3,313
New
3,312
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$747M
2
XOM icon
ExxonMobil
XOM
+$735M
3
MSFT icon
Microsoft
MSFT
+$507M
4
CVX icon
Chevron
CVX
+$429M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$427M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Financials 15.07%
2 Technology 13.69%
3 Healthcare 12.3%
4 Industrials 10.73%
5 Consumer Staples 9.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SIGA icon
2926
SIGA Technologies
SIGA
$235M
$96K ﹤0.01%
+33,967
New +$114K
EDG
2927
DELISTED
EDGEN GROUP INC CLASS A COM STK
EDG
$96K ﹤0.01%
+15,064
New +$101K
HNRG icon
2928
Hallador Energy
HNRG
$670M
$95K ﹤0.01%
+11,823
New +$87.5K
GCAP
2929
DELISTED
Gain Capital Holdings, Inc.
GCAP
$91K ﹤0.01%
+14,419
New +$76.8K
FCSC
2930
DELISTED
Fibrocell Science Inc.
FCSC
$91K ﹤0.01%
+994
New +$82.2K
TTGT icon
2931
TechTarget
TTGT
$325M
$90K ﹤0.01%
+20,163
New +$88.4K
SCMP
2932
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$90K ﹤0.01%
+13,685
New +$109K
FNM
2933
DELISTED
FANNIE MAE
FNM
$90K ﹤0.01%
+63,500
New +$90K
DRTX
2934
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$89K ﹤0.01%
+12,381
New +$90.9K
FRE
2935
DELISTED
FREDDIE MAC D/B/A VOTING
FRE
$89K ﹤0.01%
+66,008
New +$89K
PTX
2936
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$87K ﹤0.01%
+2,423
New +$90.8K
CXPO
2937
DELISTED
Crimson Exploration Inc. New Common Stock
CXPO
$86K ﹤0.01%
+30,564
New +$91.3K
SUPN icon
2938
Supernus Pharmaceuticals
SUPN
$2.59B
$84K ﹤0.01%
+12,996
New +$76.5K
ULTR
2939
DELISTED
ULTRAPETROL (BAHAMAS) LTD COM STK
ULTR
$84K ﹤0.01%
+29,620
New +$79.6K
PCYO icon
2940
Pure Cycle
PCYO
$253M
$83K ﹤0.01%
+14,930
New +$88.9K
CORT icon
2941
Corcept Therapeutics
CORT
$12.4B
$81K ﹤0.01%
+46,796
New +$84.1K
SYUT
2942
DELISTED
Synutra International, Inc.
SYUT
$81K ﹤0.01%
+15,847
New +$76.4K
ALIM
2943
DELISTED
Alimera Sciences
ALIM
$80K ﹤0.01%
+1,091
New +$63K
ISSC icon
2944
Innovative Solutions & Support
ISSC
$327M
$79K ﹤0.01%
+12,310
New +$92.9K
CIFC
2945
DELISTED
CIFC LLC Common Shares
CIFC
$77K ﹤0.01%
+10,232
New +$79.5K
VSB
2946
DELISTED
VANTAGESOUTH BANCHARES, INC
VSB
$76K ﹤0.01%
+17,306
New +$72.3K
KSPN
2947
DELISTED
Kaspien Holdings Inc. Common Stock
KSPN
$73K ﹤0.01%
+755
New +$65.9K
AMRS
2948
DELISTED
Amyris Inc.
AMRS
$72K ﹤0.01%
+1,664
New +$70.9K
TGTX icon
2949
TG Therapeutics
TGTX
$7.96B
$71K ﹤0.01%
+11,170
New +$71.5K
TTPH
2950
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$70K ﹤0.01%
+501
New +$79.3K

Similar funds

RhumbLine Advisers's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for RhumbLine Advisers, which disclosed 3,313 positions worth $31.1B. Its ten largest holdings account for 15% of the portfolio.

Its largest position is Apple: 48,576,080 shares worth $687M.

By sector, the portfolio is most concentrated in Financials at 15% of assets, followed by Technology and Healthcare.

  • RhumbLine Advisers's largest Q2 2013 buy was Apple: 48,576,080 shares worth $687M.
  • RhumbLine Advisers's ten largest holdings make up 15% of its $31.1B portfolio in Q2 2013.
  • RhumbLine Advisers disclosed 3,313 positions in Q2 2013, its first 13F filing on record.

Based on RhumbLine Advisers's 13F filing for Q2 2013, filed 7 Aug 2013.